Acurx Pharmaceuticals, Inc.

What they do

Acurx develops small molecule antibiotics that block the active site of the bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and killing Gram-positive bacteria. The pipeline targets pathogens listed as priority pathogens by the WHO, CDC and FDA, including C. difficile, MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis (anthrax). Its lead candidate, ibezapolstat, has completed a Phase 2 clinical trial in C. difficile infection; the earlier-stage candidate ACX-375C targets MRSA, VRE and PRSP. The company has no marketed products and expects to partner with a larger pharmaceutical company for late-stage trials and commercialization.

Revenue drivers

• Ibezapolstat (lead candidate) — Pre-revenue; intended as an oral and/or parenteral treatment for C. difficile infection. If approved, it would be the company's primary commercial product, but it is currently in clinical development with no sales.
• ACX-375C (early-stage pipeline) — Pre-revenue; a potential oral and parenteral treatment targeting Gram-positive bacteria including MRSA, VRE and PRSP, with proof of concept only in animal studies.
• Partnership and licensing — The company states it may partner with a fully integrated pharmaceutical company for late-stage clinical trials and commercialization, or conduct Phase 3 itself before partnering, and reviews partnership opportunities on an ongoing basis. No partnership revenue has been reported.

Recent performance

Acurx has no product revenue and has recorded net losses each year since inception: $12.7M in 2021, $12.1M in 2022, $14.6M in 2023, $14.1M in 2024 and $8.0M in 2025. Operating cash flow was negative in every year, at $5.0M, $7.5M, $9.8M, $10.4M and $6.8M for 2021 through 2025, respectively. As of June 30, 2026, the company reported total assets of $11.0M, total liabilities of $2.8M, shareholder equity of $8.2M and cash and equivalents of $10.7M. At March 31, 2025, cash was $4.6M versus $3.7M at December 31, 2024, and the company raised $2.5M in a January 2025 registered direct offering and $1.1M in a March 2025 offering plus concurrent private placement.

Strategy

The company's stated priority is advancing ibezapolstat into Phase 3 clinical trials, having received positive regulatory guidance from the EMA that it says is aligned with FDA on manufacturing, non-clinical and clinical aspects of the Phase 3 program. Acurx frames ibezapolstat as the first pol IIIC inhibitor ready for Phase 3 and has published non-clinical microbiome studies it believes differentiate the drug from vancomycin, metronidazole and fidaxomicin. It intends either to partner with a fully integrated pharmaceutical company for late-stage trials and commercialization or to run Phase 3 itself before partnering. The company has also strengthened intellectual property, including patents granted in Japan and India for DNA polymerase IIIC inhibitors expiring in December 2039, and in May 2025 closed an equity line of credit with Lincoln Park Capital for up to $12 million. It continues to evaluate strategic transactions.

Risks

• Reliance on a single lead candidate — The company states it is reliant on the success of ibezapolstat for CDI, and failure or significant delay would materially harm the business.
• No revenue and recurring losses — Acurx has incurred significant net losses in every period since inception, has no approved products and may never achieve or maintain profitability.
• Need for substantial additional funding — The company may need substantial additional capital, and failure to raise it when needed could force it to delay, reduce or eliminate development programs; raising capital may dilute existing stockholders or require relinquishing rights to product candidates.
• Clinical and regulatory risk — If serious adverse or inappropriate side effects are identified during development of ibezapolstat or other candidates, the company may need to abandon or limit development, and regulatory approval is not assured.

Outlook

Management's stated priority is to commence an international Phase 3 registration program for ibezapolstat in C. difficile infection, citing mutually consistent EMA and FDA guidance. The company continues to review partnership opportunities for late-stage development and commercialization up to FDA approval. No timeline or revenue guidance was provided in the excerpts, and the company reported no product revenue.